Adverum Biotechnologies, Inc. (ADVM) |
|
0.66 -0.018 (-2.65%)
|
12-02 16:00 |
|
Open: |
0.69 |
Pre. Close: |
0.678 |
|
High:
|
0.695 |
Low:
|
0.641 |
|
Volume:
|
682,466 |
Market Cap:
|
66(M) |
|
|
|
Technical analysis |
as of: 2022-12-02 4:20:41 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.97 One year: 1.11 |
| Support: |
Support1: 0.62 Support2: 0.52 |
| Resistance: |
Resistance1: 0.83 Resistance2: 0.95 |
| Pivot: |
0.69 |
| Moving Average: |
MA(5): 0.67 MA(20): 0.7
MA(100): 1.08 MA(250): 1.22 |
| MACD: |
MACD(12,26): -0.1  Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 22.5 %D(3): 24.4 |
| RSI: |
RSI(14): 35.8 |
| 52-week: |
High: 2.03 Low: 0.62 |
| Average Vol(K): |
3-Month: 427 (K) 10-Days: 292 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ADVM ] has closed above bottom band by 19.3%. Bollinger Bands are 61.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.7 - 0.7 |
0.7 - 0.7 |
|
Low:
|
0.63 - 0.64 |
0.64 - 0.64 |
|
Close:
|
0.65 - 0.66 |
0.66 - 0.67 |
|
Company Description |
|
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. |
Headline News |
Fri, 25 Nov 2022
Adverum Biotechnologies : Failure to Satisfy Listing Rule - Form 8-K - Marketscreener.com
Thu, 10 Nov 2022
Adverum Biotechnologies GAAP EPS of -$0.40 misses by $0.06 (NASDAQ:ADVM) - Seeking Alpha
Fri, 04 Nov 2022
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) drops to US$81m and insiders who purchased earlier this year lose another US$69k - Simply Wall St
Fri, 04 Nov 2022
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022) - Yahoo Finance
Fri, 30 Sep 2022
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD - GlobeNewswire
Wed, 07 Sep 2022
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
100 (M) |
| Shares Float |
85 (M) |
|
% Held by Insiders
|
3.6 (%) |
|
% Held by Institutions
|
64.5 (%) |
|
Shares Short
|
2,580 (K) |
|
Shares Short P.Month
|
2,660 (K) |
Stock Financials |
|
EPS
|
-1.58 |
|
EPS Est Next Qtl
|
-0.32 |
|
EPS Est This Year
|
-1.26 |
|
EPS Est Next Year
|
-1.31 |
|
Book Value (p.s.)
|
2.08 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-23 |
|
Return on Equity (ttm)
|
-56.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.82 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.46 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-115 (M) |
|
Levered Free Cash Flow
|
-84 (M) |
Stock Valuations |
|
PE Ratio
|
-0.42 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.31 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.58 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
